Six-month IVUS and two-year clinical outcomes in the EVOLVE FHU trial: a randomised evaluation of a novel bioabsorbable polymer-coated, everolimus-eluting stent

Ian T. Meredith1*, MBBS, PhD; Stefan Verheye2, MD, PhD; Neil J. Weissman3, MD; Paul Barragan4, MD; Douglas Scott5, MBChB; Mariano Valdés Chávarri6, MD, PhD; Nick E. J. West7, MD; Henning Kelbæk8, MD, DMSci; Robert Whitbourn9, MD; Darren L. Walters10, MBBS, MPhil; Jacek Kubica11, MD, PhD; Leif Thuesen12, MD; Monica Masotti13, MD, PhD; Adrian Banning14, MD; Iwar Sjögren15, MD; Rod H. Stables16, MA, DM; Dominic J. Allocco17, MD; Keith D. Dawkins17, MD

1. MonashHeart, Clayton, Victoria, Australia; 2. Ziekenhuis Netwerk Antwerpen Middelheim, Antwerp, Belgium; 3. MedStar Health Research Institute, Washington, DC, USA; 4. Polyclinique Les Fleurs, Ollioules, France; 5. Middlemore Hospital

Aims: The EVOLVE FHU trial demonstrated non-inferiority of six-month late loss with two dose formulations of SYNERGY, a novel bioabsorbable poly

Sign in to read and download the full article

Login Forgot your password?

No account yet? Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

bioabsorbable polymercoronary stenosisdrug-eluting stentseverolimustransluminal percutaneous coronary intervention

Share on Facebook Share on Twitter Share on Linkedin

Read next article

The impact of gene polymorphism and high on-treatment platelet reactivity on clinical follow-up: outcomes in patients with acute coronary syndrome after drug-eluting stent implantation